The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib (Tagrisso) will respond to therapy. But acquired resistance to the tyrosine kinase ...
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the stocks that should double by 2030. On January 29, Summit Therapeutics ...
CEO Dr Daniel Tillett talked with Proactive about the company’s launch of two new clinical programs for its lead asset, RC220 ...
Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...
Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...
Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about one-fifth to one-quarter of patients. Many brain metastases will be ...
Patients prescribed the combination therapy should be given anticoagulant prophylaxis to prevent VTE during the first 4 months of treatment. The Food and Drug Administration (FDA) has approved ...
The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's ...
Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC. On June 23, 2025, the U.S. Food and Drug ...
A multicenter, open-label, single-arm phase I/II study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm+ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results